The stock of Clovis Oncology Inc (NASDAQ:CLVS) is a huge mover today! The stock increased 3.58% or $1.23 during the last trading session, hitting $35.62. About 2.05 million shares traded hands or 19.88% up from the average. Clovis Oncology Inc (NASDAQ:CLVS) has risen 138.99% since April 26, 2016 and is uptrending. It has outperformed by 133.73% the S&P500.
The move comes after 6 months positive chart setup for the $1.26 billion company. It was reported on Nov, 29 by Barchart.com. We have $38.11 PT which if reached, will make NASDAQ:CLVS worth $88.20M more.
Analysts await Clovis Oncology Inc (NASDAQ:CLVS) to report earnings on February, 23. They expect $-1.67 earnings per share, up 25.11% or $0.56 from last year’s $-2.23 per share. After $-1.70 actual earnings per share reported by Clovis Oncology Inc for the previous quarter, Wall Street now forecasts -1.76% EPS growth.
Clovis Oncology Inc (NASDAQ:CLVS) Ratings Coverage
Out of 9 analysts covering Clovis Oncology (NASDAQ:CLVS), 4 rate it a “Buy”, 1 “Sell”, while 4 “Hold”. This means 44% are positive. Clovis Oncology has been the topic of 24 analyst reports since September 10, 2015 according to StockzIntelligence Inc. WallachBeth Capital maintained the stock with “Buy” rating in Thursday, September 10 report. As per Friday, February 26, the company rating was maintained by Stifel Nicolaus. Suntrust Robinson initiated the shares of CLVS in a report on Friday, August 5 with “Buy” rating. WallachBeth Capital maintained the shares of CLVS in a report on Monday, May 9 with “Hold” rating. The firm has “Buy” rating by Suntrust Robinson given on Wednesday, August 24. Goldman Sachs downgraded the shares of CLVS in a report on Tuesday, November 17 to “Neutral” rating. SunTrust maintained the stock with “Buy” rating in Friday, September 23 report. The stock has “Buy” rating given by Stifel Nicolaus on Wednesday, September 21. Chardan Capital Markets initiated Clovis Oncology Inc (NASDAQ:CLVS) on Tuesday, October 25 with “Sell” rating. The stock has “Buy” rating given by Suntrust Robinson on Friday, September 23.
According to Zacks Investment Research, “Clovis Oncology Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. The Company targets its development programs for the treatment of specific subsets of cancer populations. Clovis Oncology Inc. is headquartered in Colorado, USA.”
Insitutional Activity: The institutional sentiment increased to 2 in Q2 2016. Its up 1.00, from 1 in 2016Q1. The ratio improved, as 36 funds sold all Clovis Oncology Inc shares owned while 26 reduced positions. 18 funds bought stakes while 44 increased positions. They now own 36.50 million shares or 0.57% less from 36.71 million shares in 2016Q1.
Manufacturers Life Ins The holds 22,698 shares or 0% of its portfolio. Alliancebernstein L P last reported 0% of its portfolio in the stock. Atwood Palmer accumulated 0% or 100 shares. Td Asset Mngmt Inc accumulated 36,100 shares or 0% of the stock. Bourgeon Cap Management Limited Company accumulated 13,850 shares or 0.12% of the stock. Focused Wealth Mngmt has 4,865 shares for 0.03% of their US portfolio. Quantitative Systematic Strategies Limited accumulated 49,852 shares or 0.35% of the stock. Nelson Van Denburg And Campbell Wealth Management Gru Lc has invested 0% of its portfolio in Clovis Oncology Inc (NASDAQ:CLVS). The New York-based Jpmorgan Chase & Com has invested 0% in Clovis Oncology Inc (NASDAQ:CLVS). Wolverine Asset Mgmt Ltd Llc owns 10,584 shares or 0% of their US portfolio. Sabby Mngmt Ltd reported 59,836 shares or 0.04% of all its holdings. Barclays Plc accumulated 0% or 24,178 shares. Moreover, Voya Invest Management Lc has 0% invested in Clovis Oncology Inc (NASDAQ:CLVS) for 14,489 shares. Great West Life Assurance Can has 0% invested in the company for 2,793 shares. The New York-based Deerfield Mgmt has invested 0.09% in Clovis Oncology Inc (NASDAQ:CLVS).
CLVS Company Profile
Clovis Oncology, Inc., incorporated on April 20, 2009, is a biopharmaceutical firm focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Firm is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M. Rucaparib is an oral inhibitor of poly (ADP-ribose) polymerase (PARP) that is in advanced clinical development for the treatment of ovarian cancer. Lucitanib is an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors 1-3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR a/b).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.